Blog

The latest thoughts from Medicines Law & Policy partners.

Will Europe block the Pandemic Agreement because of one word?

This commentary originally appeared in the Brussels Times, and is available here. The Pandemic Agreement negotiations began in December of 2021. Sufficiently motivated by the...

Pharmaceutical Pricing Hostages

Ireland seems to be the stage of some of the most bizarre pharmaceutical company behaviour these days. This month, the pharmaceutical company CSL Behring...

Medicines Law & Policy responds to US Health and Human Services Department request for...

On 12 December 2023 the US Health and Human Services Department (HHS) posted a notice and request for comments on “the implications of access...

Why The Request By Least Developed Countries For An Extension Of The Transitional Period...

On 24 February 2015 Bangladesh on behalf of the 34 Least Developed Country members (LDCs) of the World Trade Organization (WTO) submitted a request...

Wrapping up 2020 with some noteworthy medicines, law and policy events

Wrapping up the year 2020 can’t happen soon enough. This year, one way or the other, most people on the planet have been affected...

High medicines prices in Europe – do not Brexit the people

The issues of high priced medicines and problems with access to medicines have for many years been themes belonging to the realm of global...

Access to medicines amendment of the WTO TRIPS Agreement. Hype or hope?

On 30 January 2017 the World Trade Organization (WTO) announced the first ever amendment to the TRIPS Agreement under the headline WTO members welcome...

Dutch health insurance company Menzis takes AstraZeneca to court over patent evergreening

Today health insurance company Menzis announced  that it is taking the pharmaceutical company AstraZeneca to court over the pricing of Seroquel, a medicine...

Drug Price Transparency Calls Move from South Africa to World Health Assembly

by Katrina Perehudoff and Jennifer Sellin Over 30 states and 40 business and civil society groups debated strategies for affordable and sustainable medicines prices at...

Time to put a stop to the abuse of orphan drug regulation- the latest...

Today, the Dutch Medical Journal (Nederlands Tijdschrift voor Geneeskunde) reported on the case of lutetium-octreotaat, a cancer drug developed by researchers in the Dutch...